首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study. 孕妇和哺乳期妇女流感疫苗接种犹豫及其相关因素:一项横断面研究
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-14 DOI: 10.1080/21645515.2025.2450858
Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti

Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.

由于严重流感对母亲和儿童的潜在风险,在孕妇和哺乳期妇女中实现安全的流感疫苗接种覆盖率是一项全球卫生目标。然而,疫苗犹豫仍然是接种疫苗的一个重大障碍。由于焦虑是疫苗接种决策的一个决定因素,本研究旨在评估这一人群中流感疫苗接种犹豫和焦虑水平,并探讨女性特征、她们的不情愿和焦虑水平之间的关系。在2022年2月至6月期间进行了一项多中心横断面研究,采用结构化电话访谈来评估:(1)社会人口统计学和临床病史;(2)抗流感疫苗接种情况、既往抗流感疫苗接种情况、Sars-CoV-2感染史;(3)对孕期流感疫苗接种的认识;(4)疫苗接种态度调查(VAX)量表;(5)焦虑水平,采用焦虑自评量表(SAS)测量。在387名参与者中,22.8%的人已经接种了流感疫苗或表示愿意接种流感疫苗,54%的人患有焦虑症。虽然焦虑与疫苗犹豫没有显著关联,但持续妊娠是焦虑的独立预测因素。较高的教育水平、正在怀孕、已经接种疫苗或愿意接种疫苗以及有工作与疫苗犹豫减少有关,而先前的SARS-CoV-2感染与犹豫增加有关。对不可预测事件的恐惧和缺乏卫生保健专业人员的建议成为不愿接种疫苗的原因。鉴于覆盖率较低,这些调查结果强调卫生服务部门需要加强疫苗接种工作,并提供明确建议,以打击错误信息并确保准确的疫苗安全信息。
{"title":"Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study.","authors":"Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti","doi":"10.1080/21645515.2025.2450858","DOIUrl":"10.1080/21645515.2025.2450858","url":null,"abstract":"<p><p>Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2450858"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uptake and service preferences of human papillomavirus vaccination in men who have sex with men. 男男性行为者人乳头瘤病毒疫苗接种的吸收和服务偏好。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/21645515.2024.2440956
Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee

Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (p < .001), had been tested for HPV (p = .018), and had (p = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.

人乳头瘤病毒(HPV)疫苗接种可以减少男男性行为者(MSM)的HPV感染,但在全球范围内,已发表的关于MSM接种HPV疫苗的统计数据很少。本研究估计了香港华人男男性接触者的HPV疫苗接种情况,并分析了服务偏好。通过非政府组织和在线渠道招募成年男男性行为者完成在线基线调查。使用多变量逐步logistic回归模型确定与自我报告HPV疫苗接种史相关的因素。共有701名中国MSM完成了在线基线调查,中位年龄为30岁(四分位数范围[IQR] 26-35,范围18-67),其中23%的人接受了HPV疫苗接种。超过一半接种过疫苗的男男性行为者(72%)认为当地HPV疫苗接种服务方便或非常方便。在未接种疫苗的MSM中,50%的人认为HPV疫苗的高成本是接种疫苗的障碍,67%的人表示愿意支付每剂疫苗低于128美元的费用,65%的人更愿意在私人诊所接种疫苗。接受过HIV暴露前预防(PrEP) (p = 0.018)和在过去6个月内有多个性伴侣(p = 0.005)的男男性接触者更有可能接种疫苗。在香港,中国男男性接触者的HPV疫苗接种率仍然很低(23%),HPV疫苗的高成本是主要障碍。预防行为(使用HIV PrEP和HPV检测)和高危性行为(多个性伴侣)是增加男男性接触者HPV疫苗接种率的潜在干预目标。
{"title":"Uptake and service preferences of human papillomavirus vaccination in men who have sex with men.","authors":"Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee","doi":"10.1080/21645515.2024.2440956","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440956","url":null,"abstract":"<p><p>Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (<i>p</i> < .001), had been tested for HPV (<i>p</i> = .018), and had (<i>p</i> = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440956"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China. 中国杭州 2023/24 季度流感疫苗预防就诊流感感染的有效性。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2024-12-20 DOI: 10.1080/21645515.2024.2435156
Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao

From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.

从2020年开始,流感病毒的传播在很大程度上受到全球冠状病毒病(COVID-19)大流行的影响,特别是导致B/Yamagata谱系的灭绝,并对包括该谱系在内的四价流感疫苗的相关性提出了质疑。评估疫苗对流感感染的有效性(VE)对未来的疫苗规划具有重要意义。在中国浙江省省会杭州市的五家三级医院进行了一项检测阴性病例对照研究,纳入了2023年10月1日至2024年3月31日期间出现流感样疾病(ILI)的年龄在100至6个月的住院患者。使用多变量logistic回归模型对性别、年龄、流感检测方法和流感检测时间进行校正,估计VE。在157,291名接受医疗护理的ILI参与者中,56,704人(36%)的流感检测呈阳性。针对任何医疗护理流感感染的调整后总体VE为48%(95%可信区间[CI]: 46%-51%)。三价流感灭活疫苗(IIV3)的总体VE为59% (95% CI: 50%-66%),其次是三价减毒活疫苗(LAIV3) (VE = 53%, 95% CI: 42%-62%)和四价流感灭活疫苗(IIV4) (VE = 47%, 95% CI: 45%-50%)。与IIV4相比,IIV3对医护人员感染乙型流感提供更好的保护(VE = 87%, 95% CI: IIV3为81%-92%,而IIV4为53%,95% CI: 50%-57%)。在中国杭州的2023/24流感季节,流感疫苗在重大流行病期间提供了中等保护。该结果支持了世界卫生组织关于在2023年在四价流感疫苗中排除B/山形谱系抗原的建议。
{"title":"Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China.","authors":"Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao","doi":"10.1080/21645515.2024.2435156","DOIUrl":"https://doi.org/10.1080/21645515.2024.2435156","url":null,"abstract":"<p><p>From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2435156"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment. 从PD-1/PD-L1到三级淋巴组织:为胆管癌的精准免疫治疗铺平道路
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-06 DOI: 10.1080/21645515.2024.2444697
Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen

Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified "PD-L1," "PD-1" and "pembrolizumab" as central research foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.

胆管癌(CCA)是一种高度恶性的肝胆肿瘤,其特点是治疗方案有限,预后差。近年来免疫疗法的兴起对这一领域的研究产生了重大影响。本研究采用文献计量学方法分析了从世界文献中心、万方数据、中国知网和VIP数据库中检索到的416篇论文,涵盖32个国家、589个机构和3200位作者。该分析确定“PD-L1”,“PD-1”和“pembrolizumab”为中心研究焦点,而“免疫检查点抑制剂”,“肿瘤免疫微环境”,“三级淋巴样结构”和“durvalumab”成为关键研究领域。这些发现强调了免疫治疗在改善CCA生存结果中的关键作用,并强调了肿瘤微环境中的三级淋巴结构作为未来研究的一个有希望的目标的重要性。本研究为CCA免疫疗法的发展前景提供了一个战略概述,为指导该领域未来的科学努力提供了有价值的见解。
{"title":"From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment.","authors":"Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen","doi":"10.1080/21645515.2024.2444697","DOIUrl":"https://doi.org/10.1080/21645515.2024.2444697","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified \"PD-L1,\" \"PD-1\" and \"pembrolizumab\" as central research foci, while \"immune checkpoint inhibitors,\" \"tumor immune microenvironment,\" \"tertiary lymphoid structures\" and \"durvalumab\" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2444697"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges. 提高mRNA疫苗领域主路径提取效率:一种利用中间专利、屏蔽起始和末端专利边缘的新方法。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/21645515.2025.2454078
Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang

mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.

mRNA疫苗具有突破性的技术优势和广泛的应用潜力。它们的迅速发展,特别是在2019冠状病毒病大流行期间,是数十年研究和众多技术突破的结果。这些发现相互依存,形成了密集的、相互联系的进步网络。因此,研究mRNA疫苗的技术发展路径至关重要。主路径分析对于在复杂和相互关联的网络中规划发展轨迹特别有效,是确定关键节点和创新的有力工具。本研究介绍了一种从mRNA疫苗领域专利引文网络中提取主要路径的新方法。最初,我们屏蔽了连接原点和终点专利的边缘。随后,我们从中间专利中提取主要路径,然后根据引文关系重新整合连接起始专利和终止专利的边缘,从而得到全面的主要路径提取。研究结果表明,mRNA疫苗领域的全局主路径、全局关键路径主路径、局部转发主路径和局部关键路径主路径具有一致性。主要途径的专利主要集中在核酸修饰和递送系统上。当地落后的主要路径确定了更多的专利,特别是那些与诉讼有关的专利,提供了更丰富、更多样化的技术见解。这项研究显著推进了MPA的方法学,创新的屏蔽技术为导航复杂网络提供了新的视角,并对mRNA疫苗领域的技术发展提供了更深入的了解。
{"title":"Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges.","authors":"Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang","doi":"10.1080/21645515.2025.2454078","DOIUrl":"https://doi.org/10.1080/21645515.2025.2454078","url":null,"abstract":"<p><p>mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454078"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents. mRNA-1273疫苗增强剂在青少年中的安全性和免疫原性
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-01-21 DOI: 10.1080/21645515.2024.2436714
Amparo L Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427). Binding antibody (bAb) responses against SARS-CoV-2 variants of interest and COVID-19 incidence after vaccination were also evaluated. Median boosting interval was 315 days. The mRNA-1273 booster was well-tolerated, with an acceptable safety profile. Relative to pre-booster, nAb geometric mean levels increased after the booster by 17.8-fold and 4.7-fold among pre-booster SARS-CoV-2-negative and -positive participants, respectively. Effectiveness was successfully inferred based on noninferiority of nAb levels from mRNA-1273 booster dose (Day 29) compared with nAb levels after mRNA-1273 primary series (Day 57) among young adults in COVE. Further, the booster increased bAb levels relative to pre-booster baseline against SARS-CoV-2 variants (alpha [B.1.1.7], beta [B.1.351], gamma [P.1], and delta [B.1.617.2]), regardless of pre-booster SARS-CoV-2 status. COVID-19 incidence (cases per 1000 person-months) was lower among boosted (0 cases) than non-boosted (95.766 cases) participants in January 2022, a peak period during the early omicron transmission. In summary, the mRNA-1273 50-μg booster induced robust nAb responses in previously vaccinated adolescents, regardless of SARS-CoV-2 serostatus. Effectiveness was successfully inferred and the booster was well-tolerated, with no new safety concerns identified.

在12-17岁的青少年中,评估了一种mRNA-1273 50 μg增强剂的安全性、免疫原性和有效性,增强剂前是否感染了SARS-CoV-2。在TeenCOVE试验(NCT04649151)中接受2剂量mRNA-1273 100 μg初级系列的参与者被给予mRNA-1273 50 μg加强剂。主要目的包括安全性和有效性的推断,通过建立增强剂后中和抗体(nAb)反应与nAb后初级系列mRNA-1273在COVE年轻成人(NCT04470427)中的非劣性。还评估了疫苗接种后针对感兴趣的SARS-CoV-2变体的结合抗体(bAb)应答和COVID-19发病率。中位增强间隔为315天。mRNA-1273增强剂耐受性良好,具有可接受的安全性。与强化前相比,强化前sars - cov -2阴性和阳性受试者的nAb几何平均水平分别增加了17.8倍和4.7倍。在COVE的年轻成人中,基于mRNA-1273加强剂量(第29天)与mRNA-1273初级系列(第57天)后nAb水平的非劣效性,成功推断了有效性。此外,相对于增强前针对SARS-CoV-2变体的基线,增强剂增加了bAb水平(α [B.1.1.7], β [B.1.351], γ [P。1]和δ [B.1.617.2]),无论是否为SARS-CoV-2增强剂前状态。2022年1月,接种疫苗的参与者的COVID-19发病率(每1000人月病例数)(0例)低于未接种疫苗的参与者(95.766例),这是早期基因组传播的高峰期。总之,mRNA-1273 50 μg增强剂在先前接种过疫苗的青少年中诱导了强大的nAb反应,无论其是否处于SARS-CoV-2血清状态。成功地推断了有效性,增强剂耐受性良好,没有发现新的安全问题。
{"title":"Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.","authors":"Amparo L Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy","doi":"10.1080/21645515.2024.2436714","DOIUrl":"https://doi.org/10.1080/21645515.2024.2436714","url":null,"abstract":"<p><p>Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427). Binding antibody (bAb) responses against SARS-CoV-2 variants of interest and COVID-19 incidence after vaccination were also evaluated. Median boosting interval was 315 days. The mRNA-1273 booster was well-tolerated, with an acceptable safety profile. Relative to pre-booster, nAb geometric mean levels increased after the booster by 17.8-fold and 4.7-fold among pre-booster SARS-CoV-2-negative and -positive participants, respectively. Effectiveness was successfully inferred based on noninferiority of nAb levels from mRNA-1273 booster dose (Day 29) compared with nAb levels after mRNA-1273 primary series (Day 57) among young adults in COVE. Further, the booster increased bAb levels relative to pre-booster baseline against SARS-CoV-2 variants (alpha [B.1.1.7], beta [B.1.351], gamma [P.1], and delta [B.1.617.2]), regardless of pre-booster SARS-CoV-2 status. COVID-19 incidence (cases per 1000 person-months) was lower among boosted (0 cases) than non-boosted (95.766 cases) participants in January 2022, a peak period during the early omicron transmission. In summary, the mRNA-1273 50-μg booster induced robust nAb responses in previously vaccinated adolescents, regardless of SARS-CoV-2 serostatus. Effectiveness was successfully inferred and the booster was well-tolerated, with no new safety concerns identified.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2436714"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/21645515.2025.2463191
Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni

Chikungunya virus (CHIKV), transmitted through Aedes mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of vaccine platforms used in Chikungunya vaccines that have been applied in other vaccines, focusing on adverse events of special interest (AESI) in pregnant persons, children, and adolescents. A comprehensive overview of systematic reviews (SRs) was conducted. Results: Seven systematic reviews were included and complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), and COVID-19, which share platforms with Chikungunya vaccines, showed no significant increase in AESI. Moderate-to high-quality SRs supported favorable safety profiles. Vaccines sharing platforms with Chikungunya vaccines generally exhibit acceptable safety profiles in pregnant persons, children, and adolescents.

{"title":"Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.","authors":"Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni","doi":"10.1080/21645515.2025.2463191","DOIUrl":"10.1080/21645515.2025.2463191","url":null,"abstract":"<p><p>Chikungunya virus (CHIKV), transmitted through <i>Aedes</i> mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of vaccine platforms used in Chikungunya vaccines that have been applied in other vaccines, focusing on adverse events of special interest (AESI) in pregnant persons, children, and adolescents. A comprehensive overview of systematic reviews (SRs) was conducted. Results: Seven systematic reviews were included and complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), and COVID-19, which share platforms with Chikungunya vaccines, showed no significant increase in AESI. Moderate-to high-quality SRs supported favorable safety profiles. Vaccines sharing platforms with Chikungunya vaccines generally exhibit acceptable safety profiles in pregnant persons, children, and adolescents.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2463191"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is informed consent correctly obtained for vaccinations?
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-16 DOI: 10.1080/21645515.2025.2465116
Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan

Informed consent is an integral tenet of medical ethics. However, the United States lacks a standardized consent process for immunizations, with states and private companies instead reliant on Vaccine Information Statements (VISs) introduced by the 1986 National Childhood Vaccine Injury Act. VISs, rather than being developed with patient autonomy in mind, were a response to excessive vaccine injury litigation and resulting vaccine supply shortages. VISs do not provide meaningful information disclosures, with its producer - the Centers for Disease Control and Prevention - itself admitting that VISs should not be mistaken for informed consent forms. In its content, the VIS is too complex in its readability, does not situate immunization in a public health context, and does not present all alternatives. VIS delivery is also inadequate, with limited time given for patients to digest vaccine information and no documentation required to ensure that VISs were presented at all. Simply put, VISs do little to spark deliberation and increase vaccine confidence. This article recommends minor improvements to VIS content, delivery, and accountability mechanisms to ensure distribution. The authors argue that these patient-provider moments - for patients to better understand their health, the threat of disease, and the weight of their contribution to the public - should not be squandered.

知情同意是医学伦理不可或缺的原则。然而,美国缺乏标准化的免疫接种同意程序,各州和私营公司只能依赖 1986 年《全国儿童疫苗伤害法案》引入的《疫苗信息声明》(VISs)。VISs 的制定并没有考虑到患者的自主权,而是为了应对过多的疫苗伤害诉讼和由此造成的疫苗供应短缺。VISs 并没有提供有意义的信息披露,其制作者--疾病控制和预防中心--自己也承认,VISs 不应被误认为是知情同意书。在内容上,VIS 的可读性过于复杂,没有将免疫接种置于公共卫生的背景下,也没有介绍所有的替代方案。VIS 的提供也不充分,给患者消化疫苗信息的时间有限,而且不需要任何文件来确保 VIS 的提供。简而言之,VIS 对引发深思熟虑和增加对疫苗的信心作用甚微。本文建议对 VIS 的内容、提供和问责机制稍作改进,以确保分发。作者认为,不应该浪费这些病人--提供者的时刻--让病人更好地了解自己的健康、疾病的威胁以及他们对公众所做贡献的分量。
{"title":"Is informed consent correctly obtained for vaccinations?","authors":"Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan","doi":"10.1080/21645515.2025.2465116","DOIUrl":"10.1080/21645515.2025.2465116","url":null,"abstract":"<p><p>Informed consent is an integral tenet of medical ethics. However, the United States lacks a standardized consent process for immunizations, with states and private companies instead reliant on Vaccine Information Statements (VISs) introduced by the 1986 National Childhood Vaccine Injury Act. VISs, rather than being developed with patient autonomy in mind, were a response to excessive vaccine injury litigation and resulting vaccine supply shortages. VISs do not provide meaningful information disclosures, with its producer - the Centers for Disease Control and Prevention - itself admitting that VISs should not be mistaken for informed consent forms. In its content, the VIS is too complex in its readability, does not situate immunization in a public health context, and does not present all alternatives. VIS delivery is also inadequate, with limited time given for patients to digest vaccine information and no documentation required to ensure that VISs were presented at all. Simply put, VISs do little to spark deliberation and increase vaccine confidence. This article recommends minor improvements to VIS content, delivery, and accountability mechanisms to ensure distribution. The authors argue that these patient-provider moments - for patients to better understand their health, the threat of disease, and the weight of their contribution to the public - should not be squandered.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2465116"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/21645515.2025.2474772
Abby E Rudolph, Nadine Al Akoury, Natalija Bogdanenko, Kristen Markus, Isabelle Whittle, Olivia Wright, Hammam Haridy, Julia R Spinardi, John M McLaughlin, Moe H Kyaw

This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.

{"title":"Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.","authors":"Abby E Rudolph, Nadine Al Akoury, Natalija Bogdanenko, Kristen Markus, Isabelle Whittle, Olivia Wright, Hammam Haridy, Julia R Spinardi, John M McLaughlin, Moe H Kyaw","doi":"10.1080/21645515.2025.2474772","DOIUrl":"10.1080/21645515.2025.2474772","url":null,"abstract":"<p><p>This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2474772"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2025-12-01 Epub Date: 2025-03-15 DOI: 10.1080/21645515.2025.2479229
Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng

The buildup of senescent cells exacerbates metabolic disorders in adipose tissue and contributes to aging-related cardiac dysfunction. Targeted clearance of senescent cells can markedly ameliorate these aging-related diseases. Here, we developed a novel nanovaccine (GK-NaV) loaded with seno-antigen that is self-assembled from the fusion of cationic protein (K36) and seno-antigen peptide (Gpnmb). The GK-NaV could be highly engulfed by bone marrow-derived dendritic cells (BMDCs) and efficiently present antigens on the cellular surface, thereby promoting DCs maturation and activation of CD8+T cells in vitro. Following subcutaneous immunization, GK-NaV not only exhibited a noticeable antigen depot effect but also markedly activated specific cellular immune responses, enhancing the immunoreactivity and cytotoxic effects of CD8+T cells. Consequently, the targeted anti-aging immunity triggered by GK-NaV demonstrated the ability to selectively eliminate senescent adipocytes and cardiomyocytes in high-fat diet (HFD)-induced progeroid mice, leading to a significant improvement in age-related metabolic disorders in adipose tissue and cardiac dysfunction. Hence, our findings indicate that immunization with GK-NaV targeting seno-antigens may represent a promising strategy for novel senolytic therapies.

{"title":"Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.","authors":"Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng","doi":"10.1080/21645515.2025.2479229","DOIUrl":"10.1080/21645515.2025.2479229","url":null,"abstract":"<p><p>The buildup of senescent cells exacerbates metabolic disorders in adipose tissue and contributes to aging-related cardiac dysfunction. Targeted clearance of senescent cells can markedly ameliorate these aging-related diseases. Here, we developed a novel nanovaccine (GK-NaV) loaded with seno-antigen that is self-assembled from the fusion of cationic protein (K36) and seno-antigen peptide (Gpnmb). The GK-NaV could be highly engulfed by bone marrow-derived dendritic cells (BMDCs) and efficiently present antigens on the cellular surface, thereby promoting DCs maturation and activation of CD8<sup>+</sup>T cells in vitro. Following subcutaneous immunization, GK-NaV not only exhibited a noticeable antigen depot effect but also markedly activated specific cellular immune responses, enhancing the immunoreactivity and cytotoxic effects of CD8<sup>+</sup>T cells. Consequently, the targeted anti-aging immunity triggered by GK-NaV demonstrated the ability to selectively eliminate senescent adipocytes and cardiomyocytes in high-fat diet (HFD)-induced progeroid mice, leading to a significant improvement in age-related metabolic disorders in adipose tissue and cardiac dysfunction. Hence, our findings indicate that immunization with GK-NaV targeting seno-antigens may represent a promising strategy for novel senolytic therapies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2479229"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1